2022年3月28日
Establishment of a monoclonal antibody against glycosylated CD271 specific for cancer cells in immunohistochemistry.
Cancer science
- 巻
- 113
- 号
- 8
- 開始ページ
- 2878
- 終了ページ
- 2887
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1111/cas.15340
- 出版者・発行元
- Wiley
Various proteins are highly expressed in cancer (e.g., epidermal growth factor receptor); however, the majority are also expressed in normal cells, although they may differ in expression intensity. Recently, we reported that CD271 (nerve growth factor receptor), a glycosylated protein, increases malignant behavior of cancer, particularly stem-like phenotypes in squamous cell carcinoma. CD271 is expressed in squamous cell carcinoma and in normal epithelial basal cells. Glycosylation alterations generally occur in cancer cells, therefore, we attempted to establish a cancer-specific anti-glycosylated CD271 antibody. We purified recombinant glycosylated CD271 protein, immunized mice with the protein, and screened hybridomas using an ELISA assay with cancer cell lines. We established a clone G4B1 against CD271 which is glycosylated with O-glycan and sialic acid. The G4B1 antibody reacted with the CD271 protein expressed in esophageal cancer, however, not in normal esophageal basal cells. This specificity was confirmed in hypopharyngeal and cervical cancers. G4B1 antibody recognized the fetal esophageal epithelium and Barrett's esophagus, which possess stem cell -like characteristics. In conclusion, G4B1 antibody could be useful for precise identification of dysplasia and cancer cells in SCC.
- リンク情報
- ID情報
-
- DOI : 10.1111/cas.15340
- ISSN : 1347-9032
- ISSN : 1349-7006
- ORCIDのPut Code : 110490006
- PubMed ID : 35343032
- PubMed Central 記事ID : PMC9357664